Primary prophylaxis with granulocyte colony-stimulating factor provided only a low-to-modest benefit in reducing neutropenia-related hospitalization in patients with breast cancer receiving low-to-intermediate risk chemotherapy regimens.
The risk of second-cycle febrile neutropenia was significantly higher among patients who discontinued pegfilgrastim after the first cycle.
Zarxio (filgrastim-sndz), a biosimilar of filgrastim, is efficient and well tolerated for the prophylaxis of chemotherapy-induced neutropenia.
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
Research supports use of the Exergen professional TAT-5000 temporal thermometer as a noninvasive alternative to measure temperature in adult patients to detect febrile neutropenia, found research presented at the ONS 38th Annual Congress.
Panel addresses prophylaxis and management of fever and neutropenia in cancer outpatients.
A new initiative launched by CDC is designed to reduce the risk of life-threatening infection in cancer patients undergoing chemotherapy.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|